Covid-19 disease is a nightmare for the global economy, but opening the opportunity to revive for many businesses. Biontech SE is one of those businesses, changing life into a billions of dollars after more than a decade of losses, crisis 9: 00/5: 13 years of the time, changing the transportation, is a technology company German studies, founded in 2008, with the goal of developing treatments for patients with cancer, infectious diseases to address diseases with high medical needs have not been met. Pa, right from the early years of starting, Biontech was suffering from large losses. The company falls into the situation of exhaustion, cash flow from business activities on a loss due to excessive investment costs, research and development. As of December 31, 2020, Biontech's accumulated loss was up to 409
.6 million euros. BIONTECH Department in Mainz City (Germany). Reality, during this time, Biontech is almost An anonymous company, is not even known in the German hometown, because the company does not have a product recorded in the biological map as well as the pharmaceutical in the country
By October 2019, Biontech Posted Signing offering shares for the first time (IPO) on Nasdaq (USA) and started offering shares worldwide by 2020. To maintain the company's operations, biontech must rely on talent leverage It is from the secured bank loans and issued a convertible bond. However, Biontech's activity was still blurred and stuck. At the beginning of 2020, Covid-19 epidemics outbreaks and spread to Europe, America, increasingly complex, Biontech's boss had a step Breakthrough when combined with the American pharmaceutical "giant" Pfizer to research and develop a vaccine program BNT162 against Covid-19.After 1 year of effort, December 2020, Biontech has been licensed for circulation. Conditions for Vaccine Covid-19 in more than 70 countries worldwide. In that, Biontech was authorized to market Vaccine Covid-19 in the European Union and also the owner of emergency use rights in the US (along With PFIZER), United Kingdom, Canada, Turkey and other countries, before planning a full marketing application in these countries. Pfizer has the right to market and distribute worldwide except China, Germany and Turkey. After 6 months of 2021, Biontech's revenue reached about 7.4 billion euros, an increase of 107 times compared to the first 6 months
In 2020. This number is entirely coming from Vaccine Covid-19 sales rapidly worldwide. Pre-tax profit in the first 2 quarters of 2021 reaches more than 7.9 billion euros, while last year last year hole 144 million euros. Total assets skyrocketed by 6.8 billion euros to 9.1 billion euros within 6 months. Pfizer-Biontech's 6 months. The Pfizer-Biontech changed the wall street for Biontech. The market price of Biontech's BNNTX shares almost increased non-stop, 15 times higher than the time of IPO in 2019, from 17 USD / CP (in 2019) to nearly 254.79 USD / share at the present time. Following the dream of the last 21/7, Biontech and Pfizer have shipped more than a billion dose of Vaccine Covid-19 to more than 100 countries or territories around the world. Companies signed orders about 2.2 billion doses to deliver in 2021 and more than a billion doses for 2022. BionTech's representative said the company would use the money collected from the sale of Covid-19 vaccine To continue investing in developing treatment therapies for cancer patients and infectious diseases, as well as expanding to additional areas of treatment, such as autoimmune disease, allergies, regeneration drugs and diseases Inflammation. This is also a research program that Biontech has been cherished from the date of establishment of the company but there is also a lot of components.Biontech believes that the company has a good position to develop and commercialize the therapy Next immune with the potential to transform the treatment model for many serious diseases and significantly improve clinical results for patients. However, Biontech's problems are now revenue and profit is only worth Books, reality money still has not yet obtained, due to existing receivable amounts, waiting for resolution under the profit division contract between Biontech and Pfeizer. Therefore, Biontech has a negative cash flow from business activities, leading to liquidity with many difficulties. As of June 30, 2021, Biontech has money and cash equivalents of 914.1 million euros. Biontech will receive his profit in the third quarter under the cooperation contract with PFEIZER. After the time being delayed by the effort focused on Vaccine Covid-19, Biontech has started phase 2 clinical trial for Cell therapies have previously studied research. Besides Vaccine Covid-19, Biontech is also collaborating with Pfizer to develop influenza vaccines based on the MRNA platform, starting in the 3rdd / 2021. Partners are developing vaccines against 9 different types of infectious diseases. So far, Biontech has gathered a special team of more than 2,500 employees and has established relationships with 8 for 8 . Dịch vụ:
Thiết kế website,
quảng cáo google,
đăng ký website bộ công thương uy tín
